Positions

Overview

  • Dr. de Andrade completed his medical degree in 1990 at the Federal University of Rio Grande do Sul (UFRGS) in Porto Alegre, Brazil. He went on to complete a residency in Internal Medicine at Hospital de Clinicas de Porto Alegre (UFRGS) where he also served as Chief Medical Resident. He came to the United States in 1994 and completed a residency in Internal Medicine at the University of Miami/Jackson Memorial Hospital and subsequently a fellowship in pulmonary and critical care medicine at the University of Alabama at Birmingham (UAB). He joined the faculty at UAB in 2000 and has risen to the rank of Associate Professor of Medicine. Dr. de Andrade established the UAB Interstitial Lung Disease (ILD) Program and serves as the Medical Director of the Medical ICU at the Birmingham VA Medical Center. In 2013 he was appointed Director of the Pulmonary Disease and Critical Care Medicine Fellowship Program.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2017 Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.European Respiratory Review.  26. 2017
    2017 Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis.Journal of Immunology.  199:1596-1605. 2017
    2017 More than meets the eye: IgG4-related disease presenting as isolated interstitial lung disease.Rheumatology.  56:1630-1631. 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.JCI insight.  2. 2017
    2017 3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs.JCI insight.  2:e91377. 2017
    2017 What Is in a Pattern? That Which We Call Idiopathic Pulmonary Fibrosis by Any Other Pattern Would Behave Alike!American Journal of Respiratory and Critical Care Medicine.  195:10-12. 2017
    2016 Alveolar epithelial disintegrity in pulmonary fibrosis.AJP - Lung Cellular and Molecular Physiology.  311:L185-L191. 2016
    2016 A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival.Respiratory Medicine.  115:33-38. 2016
    2016 FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.European Respiratory Journal.  47:1481-1491. 2016
    2016 Oxidative Modifications of Protein Tyrosyl Residues Are Increased in Plasma of Human Subjects with Interstitial Lung Disease.American Journal of Respiratory and Critical Care Medicine.  193:861-868. 2016
    2015 The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes.Chest.  148:1034-1042. 2015
    2015 Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis.Journal of Translational Medicine.  13:249. 2015
    2014 Development and maintenance of a biospecimen repository for clinical samples derived from pulmonary patients.Clinical and Translational Science.  7:336-341. 2014
    2014 Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.New England Journal of Medicine.  370:2093-2101. 2014
    2014 Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.Respiratory Medicine.  108:181-188. 2014
    2013 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.European Respiratory Journal.  42:1622-1632. 2013
    2013 Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.Respiratory Research.  14:73. 2013
    2013 Treatment of idiopathic pulmonary fibrosis with Ambrisentan: A parallel, randomized trialAnnals of Internal Medicine.  158:641-649. 2013
    2012 Idiopathic pulmonary fibrosis.Immunology and Allergy Clinics of North America.  32:473-485. 2012
    2012 A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine.  186:88-95. 2012
    2011 Acute exacerbations of interstitial lung diseaseClinical Pulmonary Medicine.  18:113-118. 2011
    2010 A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.New England Journal of Medicine.  363:620-628. 2010
    2010 Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results.American Journal of Respiratory and Critical Care Medicine.  181:604-610. 2010
    2009 Innovative approaches to the therapy of fibrosis.Current Opinion in Rheumatology.  21:649-655. 2009
    2009 Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.Chest.  136:237-244. 2009
    2008 BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine.  177:75-81. 2008
    2007 Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.American Journal of Transplantation.  7:2573-2578. 2007
    2007 Thoughts on the diagnosis and management of interstitial lung diseases.Southern Medical Journal.  100:555-556. 2007
    2007 Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.American Journal of Respiratory and Critical Care Medicine.  175:69-74. 2007
    2001 Association of reactive nitrogen species metabolites, myeloperoxidase, and airway inflammation in lung transplants.Journal of Investigative Medicine.  49:166-172. 2001
    2000 Protein nitration, metabolites of reactive nitrogen species, and inflammation in lung allografts.American Journal of Respiratory and Critical Care Medicine.  161:2035-2042. 2000
    1999 The lung in systemic lupus erythematosusSeminars in Respiratory and Critical Care Medicine.  20:169-178. 1999

    Research Overview

  • Because of his related interest in ILD, Dr. de Andrade has developed a strong clinical research program to study novel therapies for IPF. The UAB Interstitial Lung Disease Program was part of the NIH/NHLBI (IPFnet), which was a network of specialized centers across the country formed by the NIH in order to develop better treatments for IPF. Dr. de Andrade served on a number of committees of the IPFnet and is the Chair of the Steering Committee of the Diffuse and Interstitial Lung Disease Network of the American College of Chest Physicians. He is also a member of the Nominating Committee of the Assembly of Clinical Problems of the American Thoracic Society. He is the Director of the UAB Site of the Pulmonary Fibrosis Foundation Clinical Care Network and he also serves on the Network’s Steering Committee. Dr. de Andrade is the Principal Investigator for the UAB Pulmonary Translational Research and Clinical Database (PTREC)/Pulmonary Biospecimen Repository (in collaboration with Drs. Steven Duncan and Amit Gaggar) which aims to support UAB's clinical and translational research programs.
  • Principal Investigator On

  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2022
  • Pulmonary Fibrosis Foundation Biomarker and/or Patient Registry Protocols  awarded by University of Michigan 2015 - 2020
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease  awarded by Brigham and Women's Hospital 2018 - 2020
  • Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry (IPF_Pro)  awarded by Duke University 2014 - 2019
  • UAB Interstitial Lung Disease Program  awarded by Pulmonary Fibrosis Foundation 2015 - 2019
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2017 - 2018
  • Private Grant  awarded by Genentech 2013 - 2018
  • Private Grant  awarded by GLOBAL BLOOD THERAPEUTICS, INC. 2016 - 2018
  • Private Grant  awarded by FIBROGEN, INC. 2013 - 2018
  • Private Grant  awarded by FIBROGEN, INC. 2010 - 2017
  • Private Grant  awarded by INTERMUNE, INC. 2008 - 2015
  • Private Grant  awarded by INTERMUNE, INC. 2014 - 2015
  • Prednisone, Azathioprine, N-acetylcysteine: A Study That Evaluates Response in Idiopathic Pulmonary Fibrosis, A Randomized, Double-Blind, Placebo Controlled Trial (PANTHER-IPF)  awarded by Duke University 2009 - 2014
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2013 - 2014
  • Private Grant  awarded by MedImmune 2013 - 2014
  • Private Grant  awarded by INTERMUNE, INC. 2011 - 2014
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2011 - 2013
  • Private Grant  awarded by VERILOGUE, INC. 2013
  • Private Grant  awarded by CELGENE CORPORATION 2010 - 2013
  • Private Grant  awarded by Gilead Sciences 2013
  • Private Grant  awarded by IMMUNEWORKS 2010 - 2012
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2011 - 2012
  • Anti-Coagulant Effectiveness in Idiopathic Pulmonary Fibrosis  awarded by Duke University 2010 - 2012
  • Private Grant  awarded by Actelion Pharmaceuticals Ltd. 2009 - 2011
  • Private Grant  awarded by ACTELION CLINICAL RESEARCH, INC. 2008 - 2011
  • Private Grant  awarded by Gilead Sciences 2009 - 2011
  • Private Grant  awarded by JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC 2009 - 2011
  • Private Grant  awarded by Gilead Sciences 2009 - 2011
  • Investigator On

  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2016 - 2026
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION 2016 - 2026
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2018 - 2024
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2018 - 2023
  • Autoantibody-Targeted Therapy for Acute Exacerbations of Idiopathic Pulmonary Fibrosis  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2018 - 2022
  • Idiopathic Pulmonary Fibrosis, A Disease Initiated by Mucociliary Dysfunction  awarded by UNIVERSITY OF COLORADO DENVER - NEW 2017 - 2021
  • Private Grant  awarded by MALLINCKRODT ARD, INC 2018 - 2021
  • Private Grant  awarded by CELGENE CORPORATION 2018 - 2020
  • Private Grant  awarded by BIOGEN MA INC 2018 - 2019
  • Private Grant  awarded by BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2016 - 2019
  • Rituximab Therapy in Patients with IPF  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2015 - 2018
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease: Core C - Clinical Core  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2013 - 2018
  • Frailty as an Outcome Measure in Idiopathic Pulmonary Fibrosis  awarded by Pulmonary Fibrosis Foundation 2015 - 2017
  • Molecular Pathogenesis and Phenotype of Acquired CFTR Dysfunction in COPD  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2011 - 2016
  • Private Grant  awarded by Gilead Sciences 2013 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2014 - 2015
  • Private Grant  awarded by MedImmune 2014 - 2015
  • Education And Training

    Full Name

  • Joao de Andrade
  • Blazerid

  • joao